NIH leader fired amid probe of contract used in attempt to hire spouse, officials say
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Memphis receives two-year probation, fine from NCAA due to academic integrity violations
The University of Memphis was placed on two years probation and fined as a result of academic-integrity violations involving a counselor, softball players and men's basketball players, the NCAA announced Wednesday. The punishments were handed down after the NCAA determined former academic counselor Leslie Brooks paid two softball student-athletes to complete course work and provide quiz and test answers to a player on the men's basketball team. As a result of those findings, the school was placed on two years of probation, and received a fine of $30,000, The university was also fined one percent of the combined men's basketball and softball budgets. Brooks received a 10-year show-cause order for her involvement in the scandal. The school will also vacate all records for the games in which the men's basketball player competed while he was ineligible. This story will be updated.
Yahoo
11 minutes ago
- Yahoo
Former Police Commissioner Thomas Donlon alleges corruption, misconduct in top ranks at NYPD
NEW YORK — Thomas Donlon, a former federal agent who served as police commissioner last fall, sued Mayor Adams and top current and former NYPD officials Wednesday, alleging they operated a 'corrupt enterprise' that rewarded cronies and punished enemies at the expense of both the public and rank-and-file police officers, a copy of the suit shows. Donlon, 71, who was brought in in September 2024 after Edward Caban resigned amid a federal investigation, alleges in the 251-page complaint filed in federal court in Manhattan the department's former top spokesman Tarik Sheppard threatened to 'kill' him at the NYC Marathon after he discovered Sheppard had improperly used Donlon's rubber signature stamp to approve Sheppard's own promotion to three-star chief. 'I will f—–g kill you,' Sheppard allegedly said, according to the suit. Donlon claims former Chief of Department Jeffrey Maddrey manipulated his daily schedule, planted 'spies' in his office to keep track of what the new commissioner was doing and blocked attempts to initiate misconduct probes. Maddrey has since resigned under the cloud of a sex for overtime scandal. And Donlon claims Maddrey and Sheppard secretly switched out the names of officers he selected for promotion and replaced them with their own favorites while doctoring records to make it appear Donlon had signed off. He also alleges that after a warehouse fire in 2022 destroyed decades of evidence and exposed sloppy practices, the NYPD promised to compile a comprehensive report on evidence storage. But, Donlon alleges, no report was done and when he toured warehouses in late 2024, he found the same sloppy practices. Mayor Adams, Donlon alleges, either ignored his complaints or sided with Maddrey and his other loyalists – a major break from the past when mayors tended to back their police commissioners ahead of underlings. 'This lawsuit is not a personal grievance; it is a statement against a corrupt system that betrays the public, silences truth, and punishes integrity,' Donlon said in a statement. 'The goal is to drive real change, hold the corrupt, deceitful, and abusively powerful accountable, and restore the voice of every honorable officer who has been silenced or denied justice.' Adams appointed Donlon Sept. 13 after Edward Caban hastily resigned following a visit from federal agents involved in the then-mushrooming corruption probe. On Nov. 20, Adams summarily dismissed Donlon in favor of Jessica Tisch. Donlon was shunted to a quiet role at City Hall before he was fired in April. The lawsuit names Adams, Sheppard and seven other current and former top NYPD officials, including Maddrey, Chief of Department John Chell, First Deputy Commissioner Tania Kinsella, and now Deputy Mayor Kaz Daughtry. The suit cites federal racketeering statutes in alleging the named defendants engaged in a criminal enterprise that included obstruction of justice, honest services fraud and retaliation against a whistleblower. 'The lawsuit asserts that Adams and his deputies weaponized the NYPD's hierarchy to consolidate political control, shield sexual misconduct, and retaliate against anyone who challenged their authority,' Donlon's lawyer John Scola said. 'Donlon's refusal to play along made him a target—and the Department's values, its officers, and the public all paid the price.' Scola said the suit demands the creation of an independent federal monitor to oversee the NYPD's system of promotions, assignments, and discipline which Donlon claims are corrupted by politics It follows four lawsuits filed by top chiefs who similarly allege promotions were manipulated to benefit Adams NYPD cronies. Spokespeople for the NYPD and the Mayor's office did not immediately reply to requests for comment. ____
Yahoo
11 minutes ago
- Yahoo
UBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst Trung Huynh raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $584 from $560 while maintaining a rating ahead of the company's second-quarter earnings report. A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality. The move reflects slightly more optimistic expectations for Regeneron's financial performance, particularly driven by the continued strength of its flagship eye treatment, Eylea. The franchise has shown resilience amid increased competition in the ophthalmology space, and investor attention is likely to focus on how well Regeneron has defended its market share. Despite the upward revision, UBS remains cautious on the stock, pointing to a balance of risks and rewards in the near term. While the company has a robust pipeline and strong positioning in its core therapeutic areas, the firm believes the current share price already reflects much of the near-term optimism. The note also signals that while the broader biotech sector has experienced renewed investor interest, Regeneron's valuation leaves limited room for upside unless new catalysts emerge. The stock has performed steadily in recent months, and the upcoming earnings release may serve as a key moment for reassessing momentum into the second half of the year. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Healthcare AI Stocks to Buy According to Hedge Funds and 10 Consumer Defensive Stocks to Buy Now. Disclosure: None. This article is originally published at Insider Monkey.